Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
Spaulding C, Teiger E, Commeau P, Varenne O, Bramucci E, Slama M, Beatt K, Tirouvanziam A, Polonski L, Stella PR, Clugston R, Fajadet J, de Boisgelin X, Bode C, Carrié D, Erglis A, Merkely B, Hosten S, Cebrian A, Wang P, Stoll HP, Henry P. Spaulding C, et al. Among authors: fajadet j. JACC Cardiovasc Interv. 2011 Jan;4(1):14-23. doi: 10.1016/j.jcin.2010.10.007. JACC Cardiovasc Interv. 2011. PMID: 21251624 Free article. Clinical Trial.
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. Morice MC, et al. Among authors: fajadet j. N Engl J Med. 2002 Jun 6;346(23):1773-80. doi: 10.1056/NEJMoa012843. N Engl J Med. 2002. PMID: 12050336 Free article. Clinical Trial.
Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial.
Valgimigli M, Dawkins K, Macaya C, de Bruyne B, Teiger E, Fajadet J, Gert R, De Servi S, Ramondo A, Wittebols K, Stoll HP, Rademaker TA, Serruys PW. Valgimigli M, et al. Among authors: fajadet j. J Am Coll Cardiol. 2007 Jan 30;49(4):431-41. doi: 10.1016/j.jacc.2006.06.081. Epub 2007 Jan 12. J Am Coll Cardiol. 2007. PMID: 17258088 Free article.
Twelve month clinical and angiographic outcome after stenting of unprotected left main coronary artery stenosis with paclitaxel-eluting stents--results of the multicentre FRIEND registry.
Carrié D, Eltchaninoff H, Lefèvre T, Silvestri M, Levy G, Maupas E, Brunel P, Fajadet J, Le Breton H, Gilard M, Blanchard D, Glatt B; FRIEND. Carrié D, et al. Among authors: fajadet j. EuroIntervention. 2009 Jan;4(4):449-56. doi: 10.4244/eijv4i4a78. EuroIntervention. 2009. PMID: 19284066
Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II.
Vaina S, Voudris V, Morice MC, De Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Schuijer M, Macours N, Stoll HP, Cokkinos DV, Stefanadis C, Serruys PW; ARTSII. Vaina S, et al. Among authors: fajadet j. EuroIntervention. 2009 Jan;4(4):492-501. doi: 10.4244/eijv4i4a84. EuroIntervention. 2009. PMID: 19284072 Clinical Trial.
First-in-human feasibility and safety study of a true bifurcated stent for the treatment of bifurcation coronary artery lesions (DBS stent): six month angiographic results and five year clinical follow-up.
Dibie A, Chevalier B, Guyon P, Fajadet J, Lefèvre T, Slama MS, Royer T, Glatt B, Philippe F, Laborde F, Larrazet F. Dibie A, et al. Among authors: fajadet j. EuroIntervention. 2008 Mar;3(5):558-65. doi: 10.4244/eijv3i5a101. EuroIntervention. 2008. PMID: 19608481
Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, Cowper PA, Kong DF, Anstrom KJ. Eisenstein EL, et al. Among authors: fajadet j. JACC Cardiovasc Interv. 2009 Dec;2(12):1178-87. doi: 10.1016/j.jcin.2009.10.011. JACC Cardiovasc Interv. 2009. PMID: 20129543 Free article. Clinical Trial.
Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study.
Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Baldus S, Hauptmann KE, Suttorp MJ, Drzewiecki J, Pieper M, Schultheiss HP, Mauri L. Fajadet J, et al. EuroIntervention. 2010 Nov;6(5):562-7. doi: 10.4244/EIJV6I5A95. EuroIntervention. 2010. PMID: 21044908
269 results